Good Morning America: New Study Highlights Benefits to Weight Loss Drugs

Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, was the lead author of the STEP-HFpEF trial. 

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

The study and its results were highlighted on Good Morning America. 


Dr. Kosiborod presented the findings during the opening late breaking clinical trial session at the European Society of Cardiology Congress —the world’s largest cardiology conference— in Amsterdam, Netherlands. The results have been published in the New England Journal of Medicine at the time of the presentation.

Related Content

Aug. 25, 2023

CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds
The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Aug. 25, 2023

U.S. News & World Report: Wegovy May Be Valuable New Option for Heart Failure Patients
Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.
Aug. 25, 2023

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Heart Failure
STEP-HFpEF trial findings were presented during the opening late breaking clinical trial session at the European Society of Cardiology Congress in Amsterdam, Netherlands.